The Trump administration earlier this month rolled out new tariffs on imported pharmaceuticals alongside revised duties on metals, signaling a shift away from last year’s sweeping “Liberation Day” approach toward a more targeted trade strategy, according to Reuters.
Under the new framework, branded drug imports could face tariffs as high as 100% if manufacturers do not lower U.S. prices or shift production domestically. Reduced tariff tiers are available for partial compliance, with additional exemptions or caps tied to certain trade agreements. Companies have been given 120 to 180 days to meet the requirements.
On the metals side, covering steel, aluminum, and copper, 50% tariffs remain in place for raw materials, while many downstream products see rates reduced to 25%. Notably, tariffs will now be calculated based on U.S. sales price rather than import value, a move aimed at limiting underreporting. Products containing less than 15% metal content are exempt.
Overall, the policy reflects a compliance-driven tariff model that uses pricing and domestic production commitments as leverage while streamlining metals duties. For healthcare supply chains, the likely result is heightened cost volatility and renewed pressure to reevaluate sourcing strategies and supplier relationships.
